The European Commission has approved RINVOQ (upadacitinib) for treating non-segmental vitiligo (NSV) in adults and adolescents aged 12 and older. This marks the first systemic medication authorized in the EU for NSV, the most common form of vitiligo, based on Phase 3 Viti-Up trial data showing significant skin repigmentation and disease stabilization. Vitiligo is a chronic autoimmune condition causing white skin patches and psychological distress. RINVOQ, already approved for several immune diseases, offers a new option addressing a major unmet need in vitiligo care across Europe.
The European Commission has approved RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents 12 years and older, based on Phase 3 clinical trials demonstrating significant scalp hair regrowth and improvements in eyebrows a...
US stock futures point to a strong start with Dow Jones up 1.1%, S&P 500 up 0.9%, and Nasdaq up 1.5%, driven by a sharp 6.3% drop in oil prices following a pause in US-Iran military actions. Although no official ceasefire is declared, Iran has agreed...
AbbVie has earned a buy rating due to accelerating revenue and profit growth, supported by a reasonable valuation at 18 times forward P/E. The company offers a 2.7% forward dividend yield, outperforming its peers by 68%, and has maintained 12 consecu...
